Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease

Mark A. Moyad, Kenneth Pienta, James E. Montie

Research output: Contribution to journalArticle

Abstract

Objectives. PC-SPES, an over-the-counter supplement, is actually a combination of eight different herbs. It is being used by patients to treat cancer of the prostate at different stages of the diseases and has been commercially available since November 1996. It has been observed to dramatically decreased prostate-specific antigen (PSA) values in several patients; however, its out-of-pocket cost ($162 to $486/mo) and potential side effects must be weighted against its potential objective benefits. We reviewed its use in 1 patient. Methods. A patient with clinically localized prostate cancer (T1c) with a PSA of 8.8 ng/mL, who decided to delay any conventional treatment, began treatment with 9 PC-SPES capsules/day. Results. After 3 weeks, his PSA dropped to 1.4 ng/mL and after a total of 8 weeks, his PSA was less than 0.1 ng/mL (undetectable). He has continued on a maintenance dose of 6 capsules per day, decreasing to 4 capsules per day, with a continuing undetectable PSA. During this time the patient also experienced a number of strong estrogenic effects: loss of libido, erectile dysfunction, extreme breast enlargement and enlargement and tenderness, reduction in overall body hair, pitting edema, and a significant drop in his lipoprotein (a) level (from 46 to 11 mg/dL). Conclusions. PC-SPES may provide additive advantages (or disadvantages) over prescribed hormonal treatments but must be compared with other hormonal and nonhormonal treatments in clinical trials with hormone-sensitive and -insensitive patients with prostate cancer to determine its future use or nonuse.

Original languageEnglish (US)
Pages (from-to)319-324
Number of pages6
JournalUrology
Volume54
Issue number2
DOIs
StatePublished - Aug 1999
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Hormones
Capsules
Libido
Lipoprotein(a)
Erectile Dysfunction
Therapeutics
Health Expenditures
Hair
herbal preparation PC-SPES
Edema
Estrogens
Breast
Clinical Trials

ASJC Scopus subject areas

  • Urology

Cite this

Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease. / Moyad, Mark A.; Pienta, Kenneth; Montie, James E.

In: Urology, Vol. 54, No. 2, 08.1999, p. 319-324.

Research output: Contribution to journalArticle

@article{565a3d75cd4b481fbc8cc5e4a2885957,
title = "Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease",
abstract = "Objectives. PC-SPES, an over-the-counter supplement, is actually a combination of eight different herbs. It is being used by patients to treat cancer of the prostate at different stages of the diseases and has been commercially available since November 1996. It has been observed to dramatically decreased prostate-specific antigen (PSA) values in several patients; however, its out-of-pocket cost ($162 to $486/mo) and potential side effects must be weighted against its potential objective benefits. We reviewed its use in 1 patient. Methods. A patient with clinically localized prostate cancer (T1c) with a PSA of 8.8 ng/mL, who decided to delay any conventional treatment, began treatment with 9 PC-SPES capsules/day. Results. After 3 weeks, his PSA dropped to 1.4 ng/mL and after a total of 8 weeks, his PSA was less than 0.1 ng/mL (undetectable). He has continued on a maintenance dose of 6 capsules per day, decreasing to 4 capsules per day, with a continuing undetectable PSA. During this time the patient also experienced a number of strong estrogenic effects: loss of libido, erectile dysfunction, extreme breast enlargement and enlargement and tenderness, reduction in overall body hair, pitting edema, and a significant drop in his lipoprotein (a) level (from 46 to 11 mg/dL). Conclusions. PC-SPES may provide additive advantages (or disadvantages) over prescribed hormonal treatments but must be compared with other hormonal and nonhormonal treatments in clinical trials with hormone-sensitive and -insensitive patients with prostate cancer to determine its future use or nonuse.",
author = "Moyad, {Mark A.} and Kenneth Pienta and Montie, {James E.}",
year = "1999",
month = "8",
doi = "10.1016/S0090-4295(99)00216-2",
language = "English (US)",
volume = "54",
pages = "319--324",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease

AU - Moyad, Mark A.

AU - Pienta, Kenneth

AU - Montie, James E.

PY - 1999/8

Y1 - 1999/8

N2 - Objectives. PC-SPES, an over-the-counter supplement, is actually a combination of eight different herbs. It is being used by patients to treat cancer of the prostate at different stages of the diseases and has been commercially available since November 1996. It has been observed to dramatically decreased prostate-specific antigen (PSA) values in several patients; however, its out-of-pocket cost ($162 to $486/mo) and potential side effects must be weighted against its potential objective benefits. We reviewed its use in 1 patient. Methods. A patient with clinically localized prostate cancer (T1c) with a PSA of 8.8 ng/mL, who decided to delay any conventional treatment, began treatment with 9 PC-SPES capsules/day. Results. After 3 weeks, his PSA dropped to 1.4 ng/mL and after a total of 8 weeks, his PSA was less than 0.1 ng/mL (undetectable). He has continued on a maintenance dose of 6 capsules per day, decreasing to 4 capsules per day, with a continuing undetectable PSA. During this time the patient also experienced a number of strong estrogenic effects: loss of libido, erectile dysfunction, extreme breast enlargement and enlargement and tenderness, reduction in overall body hair, pitting edema, and a significant drop in his lipoprotein (a) level (from 46 to 11 mg/dL). Conclusions. PC-SPES may provide additive advantages (or disadvantages) over prescribed hormonal treatments but must be compared with other hormonal and nonhormonal treatments in clinical trials with hormone-sensitive and -insensitive patients with prostate cancer to determine its future use or nonuse.

AB - Objectives. PC-SPES, an over-the-counter supplement, is actually a combination of eight different herbs. It is being used by patients to treat cancer of the prostate at different stages of the diseases and has been commercially available since November 1996. It has been observed to dramatically decreased prostate-specific antigen (PSA) values in several patients; however, its out-of-pocket cost ($162 to $486/mo) and potential side effects must be weighted against its potential objective benefits. We reviewed its use in 1 patient. Methods. A patient with clinically localized prostate cancer (T1c) with a PSA of 8.8 ng/mL, who decided to delay any conventional treatment, began treatment with 9 PC-SPES capsules/day. Results. After 3 weeks, his PSA dropped to 1.4 ng/mL and after a total of 8 weeks, his PSA was less than 0.1 ng/mL (undetectable). He has continued on a maintenance dose of 6 capsules per day, decreasing to 4 capsules per day, with a continuing undetectable PSA. During this time the patient also experienced a number of strong estrogenic effects: loss of libido, erectile dysfunction, extreme breast enlargement and enlargement and tenderness, reduction in overall body hair, pitting edema, and a significant drop in his lipoprotein (a) level (from 46 to 11 mg/dL). Conclusions. PC-SPES may provide additive advantages (or disadvantages) over prescribed hormonal treatments but must be compared with other hormonal and nonhormonal treatments in clinical trials with hormone-sensitive and -insensitive patients with prostate cancer to determine its future use or nonuse.

UR - http://www.scopus.com/inward/record.url?scp=0032770547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032770547&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(99)00216-2

DO - 10.1016/S0090-4295(99)00216-2

M3 - Article

C2 - 10443732

AN - SCOPUS:0032770547

VL - 54

SP - 319

EP - 324

JO - Urology

JF - Urology

SN - 0090-4295

IS - 2

ER -